Privilège Ventures — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

Adipossadiposs.com inJan 2022

Adiposs develops ImageBAT, a contrast agent for medical imaging of brown fat that can identify patients at increased cancer risk and with higher treatment failure risk.

BiotechDigital HealthMedical Devices

Duc Tran(Chief Development Officer)

Co-investorsKickfund

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.